

<p>Identity: Title: Associate Professor Family Name(s): Savarese First Name(s): Gianluigi Age: 38</p> <p>Application for the following position in the HFA Board or Nominating Committee: Secretary</p>	<p>Photo:</p> 
--	--

Place of work	
<i>If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.</i>	
Institute/organisation:	Karolinska Institutet and Karolinska University Hospital
Department:	Department of Medicine (KI) and Department of Cardiology (KUH)
Address:	Torsplan 8
Post code / Zip:	11365 Stockholm
Country:	Sweden

General Curriculum Vitae (500 words max)
<i>Please also include your H index and top 5 to 10 publications in the last 5 years</i>
<p>CURRENT POSITION Associate Professor, Senior Lecturer and Research Team Leader (17 group members) at KI Consultant for heart failure at KUH</p> <p>BIBLIOMETRICS Overall 275 publications (156 original works, 5 book chapters, 114 reviews/editorials) – H INDEX 39</p> <p>10 IMPORTANT/LATEST ORIGINAL PUBLICATIONS</p> <ol style="list-style-type: none"> 1. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry. Guidetti F, ..., Savarese G. Eur J Heart Fail. 2023 Dec;25(12):2164-2173. 2. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Stolfo D, ..., Savarese G. Eur J Heart Fail. 2023 Sep;25(9):1648-1658. 3. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Lindberg F, ..., Savarese G. Eur J Heart Fail. 2023 Aug;25(8):1270-1280. 4. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). Savarese G, ..., Bozkurt B. JACC Heart Fail. 2023 Jan;11(1):1-14.

5. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
Janse RJ, ..., Savarese G.
Eur J Heart Fail.2022 Nov;24(11):2185-2195.
6. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.
D'Amario D, ..., Savarese G.
Eur J Heart Fail.2022 May;24(5):871-884.
7. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
Schrage B, ..., Savarese G.
Circulation.2019 Nov 5;140(19):1530-1539.
8. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
Stolfo D, ..., Savarese G.
JACC Heart Fail.2019 Jun;7(6):505-515.
9. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
Savarese G, ..., Lund LH.
JACC Heart Fail.2019 Apr;7(4):306-317.
10. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Savarese G, ..., Carrero JJ.
JACC Heart Fail.2019 Jan;7(1):65-76.

SUPERVISION

- Currently main supervisor of 5 PhD students and co-supervisor of 6 PhD students at KI.
- 2 PhD students supervised as main supervisor defended their PhD theses in 2022.
- Supervisor of 4-postdocs.

EDUCATION

- >400 certified hours of teaching
- Director of 2 PhD courses at Karolinska Institutet and 1 at Sant'Anna School of Advanced Studies in Pisa.
- Coordinator and Examiner for the KI thesis programme for medical students

RESEARCH FUNDING

~3 Millions Eur since 2019 including 3 EU Horizon grants

OTHER ACTIVITIES

- Associate Editor for European Journal of Heart Failure; Deputy Editor for EHJ-Open and EHJ-CR.
- Reviewer for grant applications for the Italian Ministry of Education, University and Research, Deutsche Forschungsgemeinschaft – DFG, British Heart Foundation.
- CEC committee: DAPA-HF, DAPA-MI, FAIR-HF2, REVASC-MI, SPIRRIT-HFpEF

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

- 2022-2024. Regular board member of the HFA
- 2020-2022. Sui Generis HFA board member
- 2022-2024. Chair of the Committee on Pharmacology and Pharmacotherapy of the HFA, and member of several HFA committees since 2020
- 2021-ongoing. Director for the HFA clinical trial course
- 2016-2020. Regular nucleus member of the ESC WG on cardiovascular pharmacotherapy
- 2018-2020. Secretary of the ESC WG on cardiovascular pharmacotherapy
- 2020-ongoing. Sui-generis nucleus member of the ESC WG on cardiovascular pharmacotherapy.
- 2022-ongoing. Contribute to the HFA newsletter, to the supervision of the HFA Young and of their activities.
- 2020-ongoing. Member of the HFA Registry committee and contributed to the design of the ESC-EORP HFIII registry.
- 2020-ongoing. Contributed to the development of several HFA position statements documents and the ESC Textbook of heart failure.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

Over the last years I have actively contributed to many HFA and ESC activities, acquiring an insight into the skills which are essential to ensure the right functioning of the Association, a fruitful collaboration between the HFA board, the ESC staff and the ESC. I am applying for the secretary position within the HFA board because I believe that my good organizational and communication skills, my strong interest for education and research, and my previous experience as secretary of the ESC WG on CVP, might allow me to significantly contribute to drive the activities of the Association and to the overall mission of the ESC. I also believe that my previous/current active participation to the activities of the Association clearly shows my commitment to serve the HFA and the ESC seriously and efficiently.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

The flexibility in scheduling my clinical and research activities provided by my institutions will allow me to dedicate the needed time to the activities of the HFA. My employment consists of 70% research and 30% clinical activity. In particular, the availability of 4 experienced post-doc within my research team would allow me to keep my research going while working on the activities of the HFA.